Eloxx Pharmaceuticals, Inc. (ELOX)
| Market Cap | 53.08M |
| Revenue (ttm) | n/a |
| Net Income | -10.65M |
| EPS | -2.84 |
| Shares Out | 4.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,757 |
| Open | 13.23 |
| Previous Close | 12.89 |
| Day's Range | 12.07 - 13.23 |
| 52-Week Range | 0.00 - 23.40 |
| Beta | -169,223.47 |
| Analysts | Strong Buy |
| Price Target | 37.50 (+185.17%) |
| Earnings Date | Aug 12, 2026 |
About ELOX
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations,... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ELOX stock is "Strong Buy." The 12-month stock price target is $37.5, which is an increase of 185.17% from the latest price.
News
Eloxx Pharmaceuticals Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
ELX-02 targets nonsense mutations in Alport syndrome and ADPKD, with Alport phase II data expected mid-2027. An ADPKD study is planned to start enrollment in Q3 2027, with data expected H1 2029; cash runway is expected into mid-2028.
Eloxx Pharmaceuticals Slides: Corporate presentation
Eloxx Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on November 9, 2026.
Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference
ARLINGTON, Mass., Nov. 2, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, tod...
Eloxx Pharmaceuticals announces FDA clearance of IND application for exaluren
Eloxx Pharmaceuticals (ELOX) announced that the U.S. FDA has cleared the company’s Investigational New Drug application for exaluren for the treatment of nonsense-mutation autosomal dominant polycysti...
Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD
FDA clearance of the IND enables Eloxx to open U.S. clinical sites for EXPRESS, its global Phase 2 study of exaluren in nonsense-mutation ADPKD EXPRESS will randomize approximately 60 patients 1:1 to ...
Eloxx Pharmaceuticals price target lowered to $40 from $43 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on Eloxx Pharmaceuticals (ELOX) to $40 from $43 and keeps a Buy rating on the shares, citing a later ADPKD timeline,…
Eloxx Pharmaceuticals appoints T.R. Srinivas as CMO
Eloxx Pharmaceuticals (ELOX) announced the appointment of T.R. Srinivas, M.D., as Senior Vice President and Chief Medical Officer. Dr. Srinivas will provide renal medical leadership across the Company...
Eloxx Pharmaceuticals finalizes Phase 2 EXPRESS study design
Eloxx Pharmaceuticals (ELOX) announced the finalized design of its EXPRESS Phase 2 global study in nonsense-mutation autosomal dominant polycystic kidney disease. Following significant interactions be...
Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D.
EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to ex aluren or placebo, with annualized htTKV growth as the primary endpoint Substantial, durable htTK...
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors
Mr. Germano brings more than 35 years of biopharmaceutical leadership experience, including as Group President of Pfizer's Global Innovative Pharmaceutical business Extensive public company board expe...
Eloxx Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Eloxx Pharmaceuticals (ELOX) with an Overweight rating. Eloxx is advancing exaluren in Phase 2 trials for Alport syndrome and autosomal dominant polycystic kidn...
Eloxx Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage of Eloxx Pharmaceuticals (ELOX) with an Overweight rating.
Leerink bullish on Eloxx Pharmaceuticals, initiates with an Outperform
As previously reported, Leerink analyst Joseph P. Schwartz initiated coverage of Eloxx Pharmaceuticals (ELOX) with an Outperform rating and $32 price target Eloxx is developing exaluren, a small molec...
Eloxx Pharmaceuticals initiated with an Outperform at Leerink
Leerink initiated coverage of Eloxx Pharmaceuticals (ELOX) with an Outperform rating and $32 price target
Eloxx Pharmaceuticals files to sell 600,000 shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 600,000 shares of common stock. The company is not selling any…
Eloxx Pharmaceuticals Registration statement: Registration filing
Eloxx Pharmaceuticals filed a registration statement on September 11, 2026, providing details about a securities offering with the SEC.
Eloxx Pharmaceuticals says first patients dosed in Phase 2b Exact Study
Eloxx Pharmaceuticals (ELOX) announced that the first two patients have been dosed in the Exact Study, a Phase 2b clinical trial evaluating exaluren in patients with nonsense mutation Alport syndrome.
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
First two patients dosed in the EXACT study Topline data from the initial 16-week placebo-controlled portion of the study expected mid-2027; final readout expected by the end of 2027 ARLINGTON, Mass.,...
Eloxx Pharmaceuticals initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of Eloxx Pharmaceuticals (ELOX) with a Buy rating and $38 price target The firm sees an attractive risk/reward ahead of the mid-2027 EXACT Phase 2b readout…
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet Phase 2b clinical trial ...
Eloxx Pharmaceuticals Quarterly report: Q2 2026
Eloxx Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 11, 2026.
Eloxx Pharmaceuticals Earnings release: Q2 2026
Eloxx Pharmaceuticals released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Eloxx Pharmaceuticals initiated with an Outperform at LifeSci Capital
LifeSci Capital analyst Rami Katkhuda initiated coverage of Eloxx Pharmaceuticals (ELOX) with an Outperform rating and $40 price target
Eloxx Pharmaceuticals initiated with a Buy at Guggenheim
Guggenheim analyst Vamil Divan last night initiated coverage of Eloxx Pharmaceuticals (ELOX) with a Buy rating and $43 price target The firm says its positive stance is driven by the…
Eloxx Pharmaceuticals initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Eloxx Pharmaceuticals (ELOX) with a Buy rating and $43 price target